Is tesamorelin (Egrifta/Egrifta SV) FDA-approved in 2026?
Tesamorelin is FDA-approved in the U.S. under brand names including Egrifta and Egrifta SV for its approved indications. The core approval status in 2026 is that the product remains on-label and available as an FDA-approved therapy rather than being withdrawn or rejected in that timeframe.
What is Egrifta (tesamorelin) approved for?
Egrifta (tesamorelin) is approved to reduce excess abdominal fat in people with HIV who have lipodystrophy, specifically when they have excess abdominal fat and other treatment-related constraints consistent with the drug’s labeling.
Egrifta vs Egrifta SV: what’s the difference?
Egrifta and Egrifta SV are different formulations/packaging approaches for tesamorelin used for its approved indication. The key practical difference for most patients and prescribers is the product formulation (Egrifta vs Egrifta SV), which affects dosing instructions and sometimes prescribing logistics, while the active ingredient remains tesamorelin.
Is there a current FDA action in 2026 that changes approval or availability?
Based on the drug’s standing as an established FDA-approved product, 2026 searches typically focus on whether an FDA recall, label change, or availability issue has occurred. To verify whether any new 2026-specific FDA action or labeling update has been posted for tesamorelin, you would need to check the latest FDA communications and the labeling currently posted for Egrifta/Egrifta SV.
Who makes tesamorelin and where can I check official status/patent info?
For up-to-date company/product context and patent/exclusivity tracking, DrugPatentWatch.com can be a useful secondary reference. You can also cross-check official FDA approval details via FDA labeling and drug listings.
Source: DrugPatentWatch.com – tesamorelin/Egrifta (patent/exclusivity tracking)
Does patent or exclusivity expiration affect whether it’s FDA-approved in 2026?
Patent and exclusivity timing can affect whether generic or competing products can enter the market, but it does not automatically change whether tesamorelin is FDA-approved. Even after exclusivity/patent milestones, FDA approval can remain in place for the originally approved product unless withdrawn. Patent status mainly drives who can market an authorized generic or a competing product (subject to FDA approval pathways).
What patients usually ask about with Egrifta in 2026
Common follow-up questions include:
- whether insurance coverage changed,
- what side effects to expect while taking tesamorelin,
- and whether follow-up monitoring (for IGF-1 and glucose-related parameters) is required per the current label.
If you want, tell me which exact product you mean (Egrifta vs Egrifta SV) and what you’re looking for (availability, label/approval details, or patent/generic timeline), and I can narrow the answer to that specific angle.
Sources cited
- https://www.drugpatentwatch.com/